Therefore, the genetic duet of BRAF V600E and TERT promoter mutations represents an effective therapeutic target in cancer, so that combined targeted therapy may improve the overall survival of melanoma patients with TERT promoter mutations. This evidence concerns the gene BRAF and melanoma.